----
Current ValuationThe current P/E ratio is 33.11, within the reasonable range, cheaper than 22.41% of the time in the past 5 years, and the industry ranks 5/58, the industry Median -2.50.
33.11xP/E
$169.09Stock price
$5.11Earnings per share
33.11xP/E
Stock price$169.09Earnings per share$5.11
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- 30.06x
- Typical range
- 27.51x–33.54x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
065130195260
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x40x80x120x160x200x
| Name/Symbol | |||
|---|---|---|---|
TMOUSThermo Fisher Scentific | 35.14x | 13.43% | $244.79B |
DHRUSDanaher | 38.36x | 16.88% | $153.60B |
AUSAgilent Tech | 33.11x | 12.34% | $47.67B |
IQVUSIQVIA | 30.90x | 0.97% | $42.48B |
MTDUSMettler Toledo | 33.93x | 10.40% | $30.73B |
MEDPUSMedpace | 34.31x | 15.08% | $16.87B |
QGENUSQiagen NV | 22.60x | 1.15% | $9.25B |
STVNUSStevanato Group SpA | 33.98x | 9.70% | $5.31B |
SHCUSSotera Health | 31.25x | 154.32% | $5.11B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
